

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	16148383
	Filing Date	2018-10-01
	First Named Inventor	Mazack et al.
	Art Unit	
	Examiner Name	
	Attorney Docket Number	C00017177US01(MED-29176/U)

U.S. PATENTS						
Examiner Initial	Cite No.	Patent Number	Kind Code	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5127404		1992-07-07	Wyborny	
	2	5192132		1993-03-09	Martha T. Pelensky	
	3	5284470		1994-02-08	Beltz	
	4	5302288		1994-04-12	Meidl	
	5	5305745		1994-04-26	Zacouto	
	6	5308315		1994-05-03	Khuri	
	7	5318750		1994-06-07	Lascombes	
	8	5399157		1995-03-21	Nicolas Goux	
	9	5441049		1995-08-15	Thomas M. Masano	
	10	5442969		1995-08-22	Troutner	
	11	5445610		1995-08-29	University of Cincinnati	
	12	5468388		1995-11-21	Goddard	
	13	5662806		1997-09-02	Baxter Int.	
	14	5683432		1997-11-04	Goedeke	
	15	5685988		1997-11-11	Paul Malchesky	
	16	5716400		1998-02-10	Smith & Nephew Inc.	
	17	5744031		1998-04-28	Bene	
	18	5762782		1998-06-09	Kenley	
	19	5849179		1998-12-15	Emerson	
	20	5858186		1999-01-12	Regents of the University of CA	
	21	5938634		1999-08-17	Baxter Int.	
	22	5938938		1999-08-17	Antonio Bosetto	
	23	5944684		1999-08-31	Roberts	
	24	6048732		2000-04-11	Anslyn	
	25	6052622		2000-04-18	Holmstrom	
	26	6058331		2000-05-02	King	
	27	6114176		1997-04-17	Gambro AB	
	28	6171480		2001-01-09	Phillip G. Lee	
	29	61760033		2013-02-01	Medtronic	
	30	6230059		2001-05-08	Duffin	
	31	6248093		2001-06-19	Moberg	
	32	6254567		2001-07-03	Treu	
	33	6321101		2001-11-20	Holmstrom	
	34	6362591		2002-03-26	Moberg	
	35	6363279		2002-03-26	Ben-Haim	
	36	6390969		2002-05-21	Orqis Medical Corporation	
	37	6521184		2003-02-18	Gambro AB	
	38	6554798		2003-04-29	Mann	
	39	6555986		2003-04-29	Moberg	
	40	6565525		2003-05-20	Vasca Inc.	
	41	6585675		2003-07-01	CHF Solutions Inc.	
	42	6589229		2003-07-08	Connely	
	43	6593747		2003-07-15	Judit E. Puskas	
	44	6596234		2003-07-22	DSU Medical	
	45	6602399		2003-08-05	Fromherz	
	46	6627164		2003-09-30	Wong	
	47	6666840		2003-12-23	Althin Medical AB	
	48	6676608		2004-01-13	Keren	
	49	6695807		2004-02-24	DSU Medical	
	50	6711439		2004-03-23	Bradley	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	16148383
	Filing Date	2018-10-01
	First Named Inventor	Mazack et al.
	Art Unit	
	Examiner Name	
	Attorney Docket Number	C00017177US01(MED-29176/U

51	6773412		2004-08-10	CHF Solutions Inc.	
52	6814724		2004-11-09	Taylor	
53	6818196		2004-11-16	Wong	
54	6878283		2005-04-12	Thompson	
55	6890315		2005-05-10	LEVIN	
56	6923782		2005-08-02	CHF Solutions Inc.	
57	6960179		2005-11-01	Gura	
58	7029456		2006-04-18	Baxter Int.	
59	7077819		2006-07-18	Goldau	
60	7097630		2006-08-29	Frank A. Gotch	
61	7128750		2006-10-31	Endoart S.A.	
62	7153693		2006-12-26	Tajiri	
63	7208092		2007-04-24	Micheli	
64	7241272		2007-07-10	Karoor	
65	7276042		2007-10-02	Polaschegg	
66	7318892		2008-01-15	Mark E. Connell	
67	7326576		2008-02-05	Prescient Medical Inc.	
68	7384543		2008-06-10	Gambro Lundia AB	
69	7462161		2008-12-09	CHF Solutions Inc.	
70	7566432		2009-07-28	Wong	
71	7575564		2009-08-18	Childers	
72	7597806		2009-10-06	Uchi	
73	7674231		2010-03-09	MCCOMBIE	
74	7674237		2010-03-09	CHF Solutions Inc.	
75	7686778		2010-03-30	NxStage Medical Inc.	
76	7704361		2010-04-27	Garde	
77	7736507		2010-06-15	Wong	
78	7754852		2010-07-13	Burnett	
79	7756572		2010-07-13	FARD	
80	7776001		2010-08-17	NxStage Medical Inc.	
81	7776006		2010-08-17	Childers	
82	7776210		2010-08-17	Rosenbaum	
83	7794141		2010-09-14	Perry	
84	7850635		2010-12-14	Polaschegg	
85	7867214		2011-01-11	Childers	
86	7901376		2011-03-08	Baxter Int.	
87	7905853		2011-03-15	Baxter Int.	
88	7922686		2011-04-12	Childers	
89	7922911		2011-04-12	Micheli	
90	7947179		2011-05-24	Rosenbaum	
91	7955289		2011-06-07	CHF Solutions Inc.	
92	7967022		2011-06-28	Grant	
93	7981082		2011-07-19	Wang	
94	8002726		2011-08-23	Karoor	
95	8034161		2011-10-11	Gura	
96	8070709		2011-12-06	Childers	
97	8080161		2011-12-20	Baxter Int.	
98	8096969		2012-01-17	Roberts	
99	8182673		2012-05-22	Baxter International Inc.	
100	8183046		2012-05-22	Lu	

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initial

<p>INFORMATION DISCLOSURE</p> <p>STATEMENT BY APPLICANT</p>	Application Number		16148383				
	Filing Date		2018-10-01				
	First Named Inventor		Mazack et al.				
	Art Unit						
	Examiner Name						
Cite No.	Publication Number	Kind Code	Publication Date	Attorney Name or Applicant of cited Document	Attorney Docket Number	C0001	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initial	Cite No.	Foreign Doc. Number	Country Code	Kind Code	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T

NON-PATENT LITERATURE DOCUMENTS

Examiner Initial	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T

EXAMINER SIGNATURE

Examiner Signature	Date Considered
/Adam Marcetich/	07/19/2021

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

/Adam Marcetich/

07/19/2021

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	16148383
	Filing Date	2018-10-01
	First Named Inventor	Mazack et al.
	Art Unit	
	Examiner Name	
	Attorney Docket Number	C00017177US01(MED-29176/U)

CERTIFICATION STATEMENT

	That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).
	OR
	That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

	See attached certification statement.
X	A certification statement is not submitted herewith.

	The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
--	---

SIGNATURE

Signature	/Roger C. Hahn/	Date (YYYY-MM-DD)	2018-11-09
Name/Print	Roger C. Hahn	Registration Number	46,376

INFORMATION DISCLOSURE	Application Number	16148383
	Filing Date	2018-10-01
	First Named Inventor	Mazack et al.
STATEMENT BY APPLICANT	Art Unit	
	Examiner Name	
	Attorney Docket Number	C00017177US01(MED-29176/U

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.